Abstracts tagged "B-Lymphocyte"

Abstract Number: 1868 • ACR Convergence 2022
B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis(JDM) is heterogenous disease with many presentations. The underlying immune pathophysiology of JDM remains complex with varying phenotypes. B Cells remain a critical…
Abstract Number: 0013 • ACR Convergence 2022
Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome
Eon Jeong Nam¹, Na Ri Kim¹ and Gun Woo Kim², ¹Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, ²Daegu Fatima Hospital, Daegu, Republic of Korea
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder with lymphocytic infiltration in exocrine and non-exocrine epithelia, in which epithelial cells play a critical role…
Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Daniel Magliulo¹, Vasileios Kyttaris¹ and Emily Rose², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, West Roxbury, MA
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
Abstract Number: 1869 • ACR Convergence 2022
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: B Cell Activating Factor (BAFF) is a cytokine that drives B Cell proliferation and maturation. B Cells remain an important factor in JDM immune…
Abstract Number: 0014 • ACR Convergence 2022
The Expanded CD21 Low B Cell Subpopulation in Ankylosing Spondylitis Consists Mainly of Antigen-Inexperienced Cells
Rick Wilbrink¹, Linda van der Weele², Anneke Spoorenberg¹, Niek De Vries², Frans Kroese¹ and Gwenny Verstappen¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Center Amsterdam, Amsterdam, Netherlands
Background/Purpose: The role of B cells in the pathogenesis of ankylosing spondylitis (AS) remains relatively understudied. Nevertheless, available evidence shows presence of B cells at…
Abstract Number: 0782 • ACR Convergence 2022
Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Christopher Halbur¹, Erin Sternhagen², Mohamad Dave Dimachkie² and Petar Lenert², ¹University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Rituximab impairs humoral immunity by depleting CD20+ B cells. Previous studies have demonstrated that patients on rituximab have decreased immune response to COVID-19 vaccination.…
Abstract Number: 2017 • ACR Convergence 2022
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
Juliette Rocca¹, Maxime Beydon², Veronique Le Guern³, Eric Hachulla⁴, Jean Jacques Dubost⁵, sandrine jousse joulin⁶, Valerie Devauchelle⁷, Jacques-Eric Gottenberg⁸, Olivier Vittecoq⁹, Christian Lavigne¹⁰, Jean Schmidt¹¹, Christian Marcelli¹², Claire Larroche¹³, Xavier Mariette¹⁴, Raphaèle Seror¹⁵ and Gaetane Nocturne¹⁶, ¹APHP, Paris, France, ²Université Paris Cité, Paris, France, ³Hôpital Cochin, Paris, France, ⁴University of Lille, LILLE, France, ⁵University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ⁶Roche, Brest, France, ⁷Université de Bretagne Occidentale, Brest, France, ⁸University of Strasbourg, Strasbourg, France, ⁹CHU de Rouen, ROUEN, France, ¹⁰CHU Angers, Angers, France, ¹¹CHU Amiens, Amiens, France, ¹²CHU Caen, Caen, France, ¹³APHP, Bobigny, France, ¹⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁵University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ¹⁶APHP, Le Kremlin Bicêtre, France
Background/Purpose: Primary Sjögren Syndrome (pSS) patients present an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management of low-grade NHL.…
Abstract Number: 0016 • ACR Convergence 2022
Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE
Yusho Ishii, James Rose, Kevin Cashman, Sakeenah Hicks, Tsuneo Deguchi, Christopher Scharer, Scott Jenks, Jeremy Boss and Iñaki Sanz, Emory University, Atlanta, GA
Background/Purpose: SLE is an autoimmune disease heterogenous for symptoms, disease severity and therapeutic response. This heterogeneity makes stratifying patients difficult. B cells from SLE patients…
Abstract Number: 0783 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases
Md Yuzaiful Md Yusof¹, Jack Arnold², Benazir Saleem³, Claire Vandevelde³, Shouvik Dass³, Sinisa Savic¹, Edward M Vital¹ and Paul Emery¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³Rheumatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: There are concerns regarding the safety of rituximab (RTX) during the COVID-19 pandemic due its effect on humoral immunity. Data from registries during pre-vaccination…
Abstract Number: 2027 • ACR Convergence 2022
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Uzma Nakshbandi¹, Martha S. van Ginkel¹, Silvia Liefers², Hendrika Bootsma², Fred Spijkervet², Arjan Vissink¹, Bert van der Vegt¹ and Frans Kroese², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
Abstract Number: 0152 • ACR Convergence 2022
Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
Erin Wilfong, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: CD19 is considered a canonical B cell lineage marker. Previously, we have reported that CD19+CD21lo/negCD11c+ cells were increased in both systemic sclerosis [PMC8828801] as…
Abstract Number: 0784 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese¹, Elizabeth Kirchner², M. Elaine Husni³, Brandon Moss², Anthony Fernandez², Yuxuan Jin³ and Leonard Calabrese³, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
Abstract Number: 0159 • ACR Convergence 2022
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
Tam Quach¹, Anne Davidson² and Galina Marder³, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Recent observations suggest the importance of the BAFF pathway in the pathogenesis of Idiopathic Inflammatory Myositis (IIM). Elevated serum levels of circulating BAFF in…
Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Susan Manzi¹, Jorge Sanchez-Guerrero², Naoto Yokogawa³, Joerg Wenzel⁴, Josephine C. Ocran-Appiah⁵, Munther Khamashta⁶, Julia H N Harris⁷, Bernie Rubin⁸, Norma Lynn Fox⁹, Roger A Levy¹⁰ and Victoria Werth¹¹, ¹Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, ³Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, ⁴University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, ⁵GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, ⁶GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, ⁷GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁹GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ¹⁰GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].